BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Synova Healthcare Inc. Release: Fem-V(TM) Profiled As 'Innovative' By Drug Topics Magazine


4/25/2006 11:00:10 AM

MEDIA, Pa., April 25 /PRNewswire-FirstCall/ -- Synova Healthcare, Inc., a subsidiary of Synova Healthcare Group, Inc. , today announced the company's soon-to-be-released Fem-V(TM) Vaginal Infection Test was recently profiled as an "innovative" over-the-counter (OTC) product by Drug Topics. Drug Topics is a twice-monthly news magazine that reports on all phases of pharmacy for community and health-system pharmacists, HMO and consultant pharmacists, chain headquarters executives and buyers, mail-order pharmacists, wholesalers, academia, and others. The article discussing Fem- V(TM), entitled "Innovative OTCs Coming To A Pharmacy Near You," was authored by Sandra Levy, and appeared in the April 17, 2006, magazine edition.

The article appears just as the first retail shipments of Fem-V(TM) have begun to make their way to retail shelves. As announced earlier, consumers will soon be able to purchase the Fem-V(TM) Vaginal Infection Test at all Rite Aid and Happy Harry's locations. In May, Fem-V(TM) will be available for purchase on approximately 3,000 store shelves.

"We are very pleased to see Fem-V(TM) gaining notoriety in various media sources, and are pleased to continue in our mission to deliver innovative, non-invasive medical diagnostics to the market," stated Ron Spangler, PhD, Chief Scientific Officer at Synova.

About Synova Healthcare Group, Inc.:

Synova Healthcare Group, Inc., (SNVH), presently operates two wholly owned subsidiaries: Synova Healthcare, Inc. and Synova Pre-Natal Healthcare, Inc. The company distributes rapid, non-invasive medical diagnostics to retail for over-the-counter (OTC) use, and directly to health care providers for point of care (POC) use in the clinical setting. The company's products are designed to improve human health and quality of life by providing early and accurate awareness of the onset of certain medical conditions.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~

This Press Release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. Such risk factors are discussed in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2005, as filed with the Securities and Exchange Commission on April 17, 2006, as well as in other periodic reports and filings with the Commission. There can be no assurance that such factors will not affect the accuracy of such forward-looking statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information set forth in this Press Release including such forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy; nor will there be any sale of securities of Synova Healthcare Group, Inc. in any state where such offer, solicitation or sale would be unlawful before registration or qualification under the securities laws of those states.

Corporate Contact Information: Synova Healthcare Group, Inc. Attn: Mr. Robert Edwards, CFO 1400 N. Providence Road, Ste. 6010 Media, PA 19063 Tel: 610-565-7080 Fax: 610-565-7081 http://www.synovahealthcare.com Inquiries may also be directed to: info@synovahealthcare.com

Synova Healthcare Group, Inc.

CONTACT: Mr. Robert Edwards, CFO, Synova Healthcare Group, Inc.,+1-610-565-7080, or Fax: +1-610-565-7081, info@synovahealthcare.com


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->